Top Markets
#1 Akedo Akedo +111.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Black Phoenix Black Phoenix +34.09%
#5 Velvet Velvet +33.20%
#6 Cross Cross +32.71%
#7 OVERTAKE OVERTAKE +17.22%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Bitway Bitway +14.87%
#10 QANplatform QANplatform +14.54%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
RepliCel Life Sciences Inc. RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

RP
Classifica tra le azioni #38779
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
Prezzo delle azioni
$0.01100905
Ultima sincronizzazione: 2025-02-28
Capitalizzazione di mercato
$810.02K
Variazione (1 giorno)
58.98%
Variazione (1 anno)
0.00%
Paese
CA
Scambia RepliCel Life Sciences Inc. (RP)

Categoria

Healthcare
Rapporto P/B per RepliCel Life Sciences Inc. (RP)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di RepliCel Life Sciences Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per RepliCel Life Sciences Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE